Published in AIDS on June 19, 2009
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet (2010) 3.90
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2014) 2.16
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep (2011) 1.65
Renal disease in HIV-infected individuals. Curr Opin HIV AIDS (2011) 1.15
Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr (2010) 1.01
Pathogen-pathogen interaction: a syndemic model of complex biosocial processes in disease. Virulence (2010) 0.98
Renal leishmaniasis as unusual cause of nephrotic syndrome in an HIV patient. J Am Soc Nephrol (2012) 0.86
The New Epidemiology of HIV-Related Kidney Disease. J AIDS Clin Res (2012) 0.86
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr (2015) 0.85
Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence. Scientifica (Cairo) (2012) 0.83
Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. Medicine (Baltimore) (2013) 0.81
Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients. AIDS (2016) 0.76
Hepatitis C Therapy in Renal Patients: Who, How, When? Infect Dis Ther (2016) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann Surg (2006) 2.65
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood (2011) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Renal perfusion assessment by renal Doppler during fluid challenge in sepsis. Crit Care Med (2013) 2.28
Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) (2004) 2.27
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 2.22
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum (2006) 2.09
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol (2009) 1.98
Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum (2007) 1.97
Behçet's disease and pregnancy. Arthritis Rheum (2013) 1.96
Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol (2011) 1.94
Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood (2008) 1.94
Antiviral drug-induced nephrotoxicity. Am J Kidney Dis (2005) 1.87
Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int (2004) 1.74
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood (2012) 1.73
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer (2007) 1.73
Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) (2014) 1.65
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int (2011) 1.64
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood (2010) 1.64
Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum (2009) 1.64
Vaccination and chronic kidney disease. Nephrol Dial Transplant (2007) 1.63
Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant (2006) 1.61
New insights into the pathogenesis of Behçet's disease. Autoimmun Rev (2011) 1.60
Ear and kidney syndromes: molecular versus clinical approach. Kidney Int (2004) 1.59
Noninvasive mechanical ventilation in patients having declined tracheal intubation. Intensive Care Med (2012) 1.56
Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum (2009) 1.55
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol (2010) 1.51
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Renal safety of tenofovir in HIV treatment-experienced patients. AIDS (2004) 1.50
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis (2007) 1.49
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant (2005) 1.49
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy. Transplantation (2011) 1.47
Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation (2002) 1.47
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol (2007) 1.46
Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14;18). J Immunol (2004) 1.45
L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol (2012) 1.44
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int (2004) 1.43
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol (2008) 1.43
Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med (2002) 1.42
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood (2003) 1.41
Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant (2003) 1.40
Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant (2005) 1.40
Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) (2014) 1.39
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum (2011) 1.38
Drug-induced Fanconi's syndrome. Am J Kidney Dis (2003) 1.38
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
[Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy]. Presse Med (2007) 1.38
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol (2002) 1.35
Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) (2012) 1.33
Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol (2005) 1.31
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev (2011) 1.29
Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog (2010) 1.27
Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS (2003) 1.27
Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS (2014) 1.27
Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs (2009) 1.26
Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis (2008) 1.25
Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med (2008) 1.24
Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum (2006) 1.21
Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol (2013) 1.20
Renal tubular drug transporters. Nephron Physiol (2006) 1.20
Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol (2012) 1.19
Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology (2002) 1.19
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. J Acquir Immune Defic Syndr (2013) 1.18
Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol (2010) 1.17
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood (2004) 1.16
Herbs and the kidney. Am J Kidney Dis (2004) 1.16
Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis (2004) 1.16
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology (2006) 1.15
Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis (2004) 1.14
Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS (2006) 1.13
Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation (2012) 1.13
Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol (2008) 1.13
Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther (2006) 1.10
Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) (2011) 1.10
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol (2009) 1.10
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol (2014) 1.10
Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev (2007) 1.08
Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant (2006) 1.08
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol (2013) 1.07
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol (2011) 1.06
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. Clin Pharmacol Ther (2002) 1.06